Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

"OPM-101 will be administered in combination with an authorized regimen of Pembrolizumab.~Pembrolizumab will be administered by IV infusion either at a dose of 200 mg every 3 weeks or at a dose of 400 mg every 6 weeks, as per Principal Investigator's decision."